within Pharmacolibrary.Drugs.ATC.C;

model C10AX13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.72,
    Cl             = 0.0023333333333333335,
    adminDuration  = 600,
    adminMass      = 0.14,
    adminCount     = 1,
    Vd             = 0.00331,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is used as a lipid-lowering agent, primarily for the treatment of hypercholesterolemia, including familial hypercholesterolemia and clinical atherosclerotic cardiovascular disease. Evolocumab is an approved drug and is used in clinical practice today, mainly as an adjunct to statins or in patients intolerant to statins.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects after subcutaneous administration. Parameters represent population means from published studies.</p><h4>References</h4><ol><li><p>Kasichayanula, S, et al., &amp; Gibbs, JP (2018). Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. <i>Clinical pharmacokinetics</i> 57(7) 769–779. DOI:<a href=&quot;https://doi.org/10.1007/s40262-017-0620-7&quot;>10.1007/s40262-017-0620-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29353350/&quot;>https://pubmed.ncbi.nlm.nih.gov/29353350</a></p></li><li><p>Tomlinson, B, et al., &amp; Liu, ZM (2017). Evolocumab for the treatment of hypercholesterolemia. <i>Expert opinion on biological therapy</i> 17(11) 1447–1461. DOI:<a href=&quot;https://doi.org/10.1080/14712598.2017.1365134&quot;>10.1080/14712598.2017.1365134</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28812389/&quot;>https://pubmed.ncbi.nlm.nih.gov/28812389</a></p></li><li><p>Kuchimanchi, M, et al., &amp; Doshi, S (2018). Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. <i>Journal of pharmacokinetics and pharmacodynamics</i> 45(3) 505–522. DOI:<a href=&quot;https://doi.org/10.1007/s10928-018-9592-y&quot;>10.1007/s10928-018-9592-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29736889/&quot;>https://pubmed.ncbi.nlm.nih.gov/29736889</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C10AX13;
